Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed hair regrowth and increased density in four cases of androgenetic alopecia treated with a non-ablative erbium glass fractional laser and topical finasteride, with no significant side effects reported.

This study found that transdermal DHT treatment increased penile length in boys with 5α-reductase type 2 deficiency, but post-pubertal growth was limited and carried potential prostate complications.

Finasteride and minoxidil together safely and effectively increase hair growth and density for androgenetic alopecia.

This study found that dutasteride use is associated with increased reports of sexual dysfunction, based on data from the U.S. Food and Drug Administration Adverse Event Reporting System.

This study found that oral dutasteride increased hair count more than intralesional administration in androgenetic alopecia, but more research is needed for a reliable comparison.

This meta-analysis reported that finasteride 1 mg/day significantly increased hair count in male androgenetic alopecia compared to placebo, but highlighted persistent sexual side effects and associated depression risk.

This meta-analysis concluded that 5α-reductase inhibitors may increase the risk of mild depression, particularly with dutasteride, in patients treated for benign prostatic hyperplasia and androgenic alopecia.

Finasteride lowers prostate cancer risk but may increase high-grade tumors and sexual side effects.

This study found that autologous platelet-rich plasma treatment significantly increased the number of hairs in male patients with androgenetic alopecia.

This study found that dutasteride mesotherapy increased the diameter of existing hair in five Mexican men with androgenetic alopecia, without reported side effects.

This study reported that finasteride 1 mg/day significantly increased hair growth and slowed hair loss in men with frontal scalp hair thinning over one year, and these benefits continued or improved in the second year.

This study found that 5α-reductase inhibitors significantly increase the risk of erectile dysfunction and hypoactive sexual desire in men with benign prostatic hyperplasia, compared to placebo.

This study found that finasteride (1 mg) significantly increased hair growth in all scalp regions affected by male pattern hair loss over 24 months in men aged 18 to 60, with more pronounced effects in younger men.

This study found that 5-α reductase inhibitors do not significantly increase the risk of erectile dysfunction in men with benign prostatic hyperplasia or alopecia, although duration of benign prostatic hyperplasia may elevate risk.

This study found that topical application of Serenoa repens extract increased hair count in men with androgenetic alopecia, suggesting it could be an alternative for those unable to use standard medications.

Finasteride and baicalin in phospholipid vesicles effectively promote hair growth and increase follicle count.

This study found that finasteride use for androgenetic alopecia was not associated with increased sexual dysfunction compared to an age-matched control group.

This study found that combining oral testosterone with dutasteride increased testosterone bioavailability in hypogonadal men while suppressing dihydrotestosterone levels over a 28-day period.

This study found that the non-steroidal antiandrogen RU58841 increased hair growth rates and promoted hair cycle initiation in balding human scalp grafts on testosterone-conditioned nude mice, indicating a positive effect on hair growth.

In this study, complexation with cyclodextrins was reported to increase the solubility of FIN for potential use in aqueous formulations for treating male androgenic alopecia.

This retrospective study found that treatment with autologous plasma rich in growth factors increased hair density and improved hair follicle health in patients with androgenetic alopecia, with no reported adverse effects.

This review discusses the potential link between androgen deficiency and increased COVID-19 severity in aging men, but reports no new clinical results; it suggests that low testosterone levels may pose a risk factor.

This study found that a topical herbal solution significantly increased hair diameter and density in men with androgenetic alopecia compared to minoxidil after 36 weeks of treatment.

This study on rats found that finasteride and dutasteride increased collagen density in penile tissues and caused changes in prostate cells, but did not significantly alter erectile pressures compared to controls.

Finasteride is safe for hair loss treatment and doesn't increase high-grade prostate cancer risk.

This study found that methanolic extract of Cordia plathytyrsa increased testosterone levels in male rats but did not affect other evaluated metabolic parameters.

This study found that using gallate-containing formulations like EGCG or tannic acid increased the solubility and controlled release of finasteride in microspheres, enhancing its dermal penetration in pig skin by 10 to 50 times compared to a control.

This study demonstrated that herbal therapy with oil extract increased triglyceride content in dog hair, suggesting potential benefits on coat quality that require further investigation.

This research review discusses the potential link between androgenetic alopecia and increased cardiovascular risk but does not report any new experimental findings.

In this study, PRP injections increased hair count and reduced hair loss in patients with androgenic alopecia not responding to minoxidil and finasteride, with high patient satisfaction reported.